KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest Expenses (2016 - 2026)

Pacira BioSciences has reported Interest Expenses over the past 17 years, most recently at $3.7 million for Q1 2026.

  • For Q1 2026, Interest Expenses fell 19.24% year-over-year to $3.7 million; the TTM value through Mar 2026 reached $16.6 million, down 7.11%, while the annual FY2025 figure was $17.4 million, 5.29% up from the prior year.
  • Interest Expenses for Q1 2026 was $3.7 million at Pacira BioSciences, down from $3.9 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $11.0 million in Q4 2022 and troughed at $3.3 million in Q1 2024.
  • A 5-year average of $5.8 million and a median of $4.6 million in 2025 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: skyrocketed 46.98% in 2022 and later crashed 69.31% in 2023.
  • Year by year, Interest Expenses stood at $11.0 million in 2022, then plummeted by 69.31% to $3.4 million in 2023, then surged by 38.13% to $4.7 million in 2024, then decreased by 16.84% to $3.9 million in 2025, then dropped by 4.96% to $3.7 million in 2026.
  • Business Quant data shows Interest Expenses for PCRX at $3.7 million in Q1 2026, $3.9 million in Q4 2025, and $4.3 million in Q3 2025.